Sascha Haubner

A cell intrinsic NKG2A/C switch receptor to overcome the critical HLA-E checkpoint. Fun collaboration with the Michel Sadelain lab. Michelle Sætersmoen, Ivan Kotchetkov, @LambertoTR @CoE_PRIMA @UniOslo_MED @Oslounivsykehus @CIM_Sweden

Online Now: Co-op CARs for targeting acute myeloid leukemia dlvr.it/SxWLLy

“IF-BETTER” combinatorial chimeric co-stimulatory receptor with an attenuated CAR enhances AML killing while protecting healthy progenitors, highlighting potential to leverage cooperative CAR designs cell.com/cancer-cell/fu… @Michel_Sadelain @HaubnerSascha cell.com/cancer-cell/pd…

AML cells are heterogeneous and share protein expression with healthy HSPCs. To target AML and spare HSPC toxicity, @HaubnerSascha @michel_sadelain @MSKCancerCenter combined a sensitivity-tuned CAR for ADGRE2 [...] bit.ly/3LWkdoq

MSK’s @HaubnerSascha and the @michel_sadelain lab develop a novel #CART approach for treating #AML, minimizing antigen escape and toxicities. The immunotherapy targets both ADGRE2 and CLEC12A. Read more in @Cancer_Cell.

Interesting paper came out. “HSC shielding” is definitely not the only mean to evade therapy toxicities for the treatment of malignant disorders. cell.com/cancer-cell/fu…

Out now: New paper from the Sadelain lab. Congrats to all authors!

Online Now: Cooperative CAR targeting to selectively eliminate AML and minimize escape dlvr.it/Sx529Z

Cooperative CAR targeting strategy w/ ADCLEC.syn1 operating via CCR-gated sensitivity and thereby overcomes antigen escape in heterogeneous AML and reduces on-target toxicity in humanized mice @Michel_Sadelain cell.com/cancer-cell/fu…